Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
9 hours ago · Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug Leqembi’s (lecanemab) sales growth is expected to stay gradual ...
Samsung Bioepis, Biogen Get European Commission ... - Markets …
15 hours ago · (RTTNews) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) Monday announced that the European Commission (EC) has approved Opuviz, a biosimilar to Regeneron Pharmaceuticals' Aflibercept. Opuviz ...
5 Reasons Biogen’s Shares Have Dropped 36% in 2024
5 days ago · Spinraza sales dropped $67 million to $381 million for the third quarter, which Biogen attributed to the loss of an annual tender in Russia. The drug has also suffered due to competition from Novartis’ gene therapy Zolgensma. Biogen is hoping that Spinraza can return to growth, potentially in combination with Zolgensma.
News - Biogen
Oct 30, 2024 · Biogen Reports Third Quarter 2024 Results. Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases. Biogen Appoints Daniel Quirk, MD, …
Biogen Announces Positive Topline Results from Study of Higher …
Sep 4, 2024 · Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational dose regimen; Higher dose nusinersen regimen showed statistically significant improvement compared to a prespecified matched sham control group
Biogen Receives U.S. FDA Breakthrough Therapy Designation for ...
CAMBRIDGE, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – Biogen announced today that felzartamab, an investigational anti-CD38 monoclonal antibody, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of late antibody-mediated rejection (AMR) without T ...
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs …
Oct 30, 2024 · (Bloomberg) -- Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new Alzheimer’s treatment.
Biogen discontinues Alzheimer’s medication Aduhelm - CNN
Jan 31, 2024 · The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the company...
Needham downgrades Biogen on slow growth of Alzheimer's drug
11 hours ago · Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.
Biogen cut to hold by Needham on lack of catalysts, slow …
1 day ago · Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s Alzheimer’s drug Leqembi. The investment bank said it doesn ...